News
-
One PBS addition for Dec
Monday | Dec 4 2017JUST one medicine has been added to the Pharmaceutical Benefits Scheme this month, with funding approved for eribulin (Halaven) for the treatment of soft tissue sarcoma.
-
Pharmacy of the future
Monday | Dec 4 2017THE Pharmacy Guild of Australia has revealed further details of its "Community Pharmacy in 2025" research project (PD 14 Sep), with the appointment of consultant group Pottinger as strategic adviser.
-
Dispensary Corner 01 Dec 17
Friday | Dec 1 2017THE Polish Government has resorted to an advertisement using the legendary enthusiasm of rabbits for breeding to up the country's birth rate.
-
Aussie ECP on the world stage
Friday | Dec 1 2017JOHN Ly, owner of Imes Pharmacy in South Melbourne (pictured) has been elected as the Chairperson of the International Young Pharmacists Group for the International Pharmaceutical Federation.
-
Biosimilar summary
Friday | Dec 1 2017THE Department of Health has published a summary setting out the biosimilar brands of medicines which have been approved by the Therapeutic Goods Administration and subsidised on the Pharmaceutical Benefits Scheme.
-
Invest in PBS – MA
Friday | Dec 1 2017MEDICINES Australia (MA) has called upon the Federal Government to prioritise investment in the Pharmaceutical Benefits Scheme to improve access to all cancer medicines.
-
Pharmacist jobs tick
Friday | Dec 1 2017PHARMACY students are among the most likely professionals to gain jobs soon after graduation, according to the 2017 Graduate Outcomes Survey - qilt.edu.au.
-
Vic pharmacist facing charges
Friday | Dec 1 2017A committal hearing into the case of a 39-year-old pharmacist in Victoria's Latrobe Valley accused of trafficking prescription drugs and illicit substances has been adjourned, after the magistrate asked for time to deliberate.
-
Flo free with saline
Friday | Dec 1 2017NPS MedicineWise has posted a special page on managing hay fever symptoms making reference to antihistamines, corticosteroids, decongestants and a new entrant, saline drops or spray.
-
Novartis to STRIVE for migraines
Friday | Dec 1 2017SWISS pharmaceutical giant Novartis has announced Phase III STRIVE data published in NEJM demonstrating significant and sustained efficacy of erenumab in migraine prevention.
